Antiviral treatment of COVID-19: An update.

  title={Antiviral treatment of COVID-19: An update.},
  author={Serap Simşek Yavuz and Feride Ipek Komsuoğlu Çelikyurt},
  journal={Turkish journal of medical sciences},
Currently there is not an effective antiviral treatment for COVID-19, but a large number of drugs have been evaluated since the beginning of the pandemic and many of them have been used for the treatment of COVID-19 despite the preliminary or conflicting results of the clinical trials. We aimed to review and summarize all of the current knowledge on the antivirals for COVID-19. There are 2 main drug groups for SARS-CoV-2: Agents that target proteins or RNA of the virus or interfere with… 

An Update of Carbazole Treatment Strategies for COVID-19 Infection

The observations reported in this review about carbazoles as a treatment can signify a potentially useful clinical application; various drugs that can be introduced into the therapeutic equipment to fight COVID-19 or their molecules can be used as the basis for designing new antivirals.

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study

In this work, the discovery and description of PF-07321332, a major bioavailable oral SARS-CoV-2 protease inhibitor with in vitro human coronavirus antiviral activity, and excellent selection of

Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

  • M. McCarthy
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2022
Current therapeutic approaches, including the use of immunomodulators such as corticosteroids, interleukin inhibitors, kinase inhibitors, fluvoxamine, and ivermectin are examined, and the ways that these therapies and others may be used to treat COVID-19 in the future are explored.

Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review

The candidate small-molecule anti-SARS-CoV-2 drugs in ongoing clinical trials are reviewed, with a major focus on their mechanisms of action in an attempt to provide useful insight for further research and development of small- molecule compounds against SARS- CoV- 2 infection.

The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics

Nbs are a viable option to target SARS-CoV-2 and overcome COVID-19 and advantages of Nbs are discussed, which allow for rapid Nb generation, inexpensive large-scale production, effective storage, and transportation, which is essential during pandemics.

Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus

The molecular mechanism of CoV infection cycle, including the receptor binding, viral entry, intracellular replication, virion assembly, and release is presented, and a summary of anti-viral peptides that have been reported in peer-reviewed publications are provided.

Nirmatrelvir–remdesivir association for non-hospitalized adults with COVID-19, point of view

The evidence in the literature on the monotherapy use of paxlovid and monotherapyuse of remdesivir, and the scientific hypothesis of using nirmatrelvir and remdesvir in association with the aim of increasing treatment efficacy, reducing the risk of adverse reactions and generating antiviral drug-resistant variants are described.

A Spotlight on the Development, Pharmaceutical Trends, Innovations and Patents of Nirmatrelvir (PaxlovidTM)

Research studies conducted have proven the efficacy of this oral anti-viral drug in mild to moderate COVID-19 patients beside its ease of oral administration and good oral bioavailability.